Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biosimilar symbols : Nvsef save search
Biosimilar Lymphocyte Modulator Global Market Report 2024 - Robust 10.6% CAGR Forecast, Amid Rising Autoimmune Disease Prevalence
Published: 2024-02-20 (Crawled : 03:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -0.95%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 2.91%
H: 0.35%
C: -0.38%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: -0.69%
H: 1.24%
C: 0.76%
disease biosimilar report global market
Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances
Published: 2024-02-14 (Crawled : 20:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.26%
H: 0.87%
C: 0.32%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
biosimilar report global therapy growth market
FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
Published: 2023-12-07 (Crawled : 00:00) - biospace.com/
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.97%
H: 0.3%
C: -0.19%
avzivi fda biosimilar
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published: 2023-10-03 (Crawled : 13:00) - biospace.com/
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 2.22%
H: 0.87%
C: -0.65%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.6%
H: 0.36%
C: -0.46%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -1.67%
xolair biosimilar commercialization agreement
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published: 2023-10-03 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 2.22%
H: 0.87%
C: -0.65%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.6%
H: 0.36%
C: -0.46%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -1.67%
xolair biosimilar commercialization agreement
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
adl018 xolair candidate biosimilar study
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -3.05%
H: 1.75%
C: 0.5%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.07%
H: 0.46%
C: -0.31%
tyruko europe biosimilar approval sclerosis
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Published: 2023-09-18 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -1.31%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.06%
H: 0.09%
C: -0.6%
biosimilar chmp breast positive cancer
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Published: 2023-08-25 (Crawled : 06:00) - globenewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
tyruko fda biosimilar approval sclerosis
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Published: 2023-08-15 (Crawled : 06:00) - globenewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.44%
biosimilar positive results study
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
Published: 2023-07-24 (Crawled : 06:00) - globenewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.05%
H: 0.24%
C: -0.83%
biosimilar chmp positive sclerosis
Sandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline
Published: 2023-07-20 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.78%
H: 0.0%
C: -1.86%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 1.51%
H: 0.72%
C: 0.33%
biosimilar pipeline growth
United States Biosimilar Market Report 2023: Sector is Expected to Reach $50.68 Billion in 2027 at a CAGR of 40.17%
Published: 2023-06-30 (Crawled : 19:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
biosimilar report expected reach market
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
Published: 2023-06-15 (Crawled : 06:00) - globenewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 1.04%
H: 0.78%
C: 0.67%
biosimilar
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Published: 2023-05-25 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -0.89%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: -1.2%
biosimilar authorization ema
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Published: 2023-03-21 (Crawled : 15:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: -1.15%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.25%
H: 0.19%
C: 0.04%
hyrimoz fda biosimilar approval
Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines
Published: 2023-03-09 (Crawled : 13:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -5.6%
H: 1.19%
C: 1.19%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -3.04%
H: 0.16%
C: -0.9%
global biosimilar
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Published: 2023-02-06 (Crawled : 07:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -2.93%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.12%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.62%
fda biosimilar application license
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Published: 2023-01-30 (Crawled : 07:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.65%
H: 0.37%
C: -0.48%
biosimilar chmp positive
Biosimilar Therapeutic Peptides Global Market to Reach $3.5 Billion by 2026 at a CAGR of 30.3%
Published: 2022-12-06 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.74%
H: 8.46%
C: 8.46%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.97%
H: 0.05%
C: 0.05%
NVO | News | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.85%
H: 0.46%
C: -0.17%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.03%
H: 0.26%
C: -0.27%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.48%
H: 1.59%
C: 0.69%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.33%
H: 0.56%
C: -0.89%
global biosimilar market
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.